A bill to provide for certain causes of action relating to delays of generic drugs and biosimilar biological products.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Senator for Vermont. Democrat.
Last Updated: Jun 14, 2016
Length: 25 pages
Jun 14, 2016
114th Congress, 2015–2017
Died in a previous Congress
This bill was introduced on June 14, 2016, in a previous session of Congress, but was not enacted.
Jun 14, 2016
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
Apr 27, 2017
Reintroduced Bill — Introduced
This activity took place on a related bill, S. 974.
S. 3056 (114th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
Civic Impulse. (2018). S. 3056 — 114th Congress: CREATES Act of 2016. Retrieved from https://www.govtrack.us/congress/bills/114/s3056
“S. 3056 — 114th Congress: CREATES Act of 2016.” www.GovTrack.us. 2016. May 27, 2018 <https://www.govtrack.us/congress/bills/114/s3056>
|title=S. 3056 (114th)
|accessdate=May 27, 2018
|author=114th Congress (2016)
|date=June 14, 2016
|quote=CREATES Act of 2016
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.